ASCO 2014 - Results from #20

#ASCO14 - Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: An ECOG-led phase III randomized trial - Session Highlights June 2, 2014

#ASCO14 - Poster: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study June 1, 2014

#ASCO14 - Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) - Session Highlights June 1, 2014

#ASCO14 - Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma - Session Highlights June 1, 2014

#ASCO14 - Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study - Session Highlights June 1, 2014

#ASCO14 - Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer (UBC) - Session Highlights June 1, 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in men with metastatic, hormone-sensitive prostate cancer June 1, 2014

#ASCO14 - Poster: Circulating tumor cell count and lactate dehydrogenase levels are prognostic factors in patients with metastatic CRPC progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial May 31, 2014

#ASCO14 - Poster: ARN-509 in patients with metastatic castration-resistant prostate cancer with and without prior abiraterone acetate treatment May 31, 2014

#ASCO14 - Poster: Phase 1b study of abiraterone acetate and docetaxel in patients with metastatic castration-resistant prostate cancer May 31, 2014

#ASCO14 - Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) - Session Highlights May 31, 2014

Early, phone-based, palliative care support improves caregiver quality of life May 30, 2014

Discontinuing statins near the end of life is safe, improves patient quality of life May 30, 2014

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing May 28, 2014

2014 ASCO Annual Meeting press program to highlight major advances in cancer research April 29, 2014

Page 2 of 2